Rapid conversion of the ester prodrug abiraterone acetate results in intestinal supersaturation and enhanced absorption of abiraterone: In vitro, rat in situ and human in vivo studies

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 90, Issue , 2015, Pages 1-7

  Stappaerts, Jef ^a   Geboers, Sophie ^a   Snoeys, Jan ^b   Brouwers, Joachim ^a   Tack, Jan ^c   Annaert, Pieter ^a   Augustijns, Patrick ^a  

^a DEPARTMENT OF PHARMACEUTICAL AND PHARMACOLOGICAL SCIENCES   (Belgium)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Abiraterone; Ester prodrug; Human intestinal fluids; Intestinal perfusion; Intraluminal degradation; Intraluminal supersaturation

Indexed keywords

ABIRATERONE; ABIRATERONE ACETATE; ESTERASE; ESTER; PRODRUG;

ANIMAL EXPERIMENT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DISPOSITION; DRUG SOLUBILITY; DRUG STABILITY; DUODENUM FLUID; HUMAN; HYDROLYSIS; IN VITRO STUDY; IN VIVO STUDY; INTESTINE ABSORPTION; INTESTINE FLUID; INTESTINE PERFUSION; MALE; NONHUMAN; NORMAL HUMAN; RAT; SUSPENSION; ADULT; ANIMAL; INTESTINE; METABOLISM; ORAL DRUG ADMINISTRATION; PHYSIOLOGY; SOLUBILITY; SPRAGUE DAWLEY RAT; YOUNG ADULT;

ABIRATERONE ACETATE; ADMINISTRATION, ORAL; ADULT; ANIMALS; ESTERS; HUMANS; INTESTINAL ABSORPTION; INTESTINES; MALE; PRODRUGS; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY; YOUNG ADULT;

EID: 84921798727     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2015.01.001     Document Type: Article

References (12)

1. K. Masaki, M. Hashimoto, T. Imai, Intestinal first-pass metabolism via carboxylesterase in rat jejunum and ileum, Drug Metab. Dispos. 35 (2007) 1089-1095, http://dx.doi.org/10.1124/dmd.106.013862.
2. A.S. Borde, E.M. Karlsson, K. Andersson, K. Björhall, H. Lennernäs, B. Abrahamsson, Assessment of enzymatic prodrug stability in human, dog and simulated intestinal fluids, Eur. J. Pharm. Biopharm. 80 (2012) 630-637, http://dx.doi.org/10.1016/j.ejpb.2011.11.011.
3. J. Brouwers, J. Tack, P. Augustijns, In vitro behavior of a phosphate ester prodrug of amprenavir in human intestinal fluids and in the Caco-2 system: illustration of intraluminal supersaturation, Int. J. Pharm. 336 (2) (2007) 302-309.
4. G.E. Granero, G.L. Amidon, Stability of valacyclovir: implications for its oral bioavailability, Int. J. Pharm. 317 (2006) 14-18, http://dx.doi.org/10.1016/j.ijpharm.2006.01.050.
5. K. Stoeckel, W. Hofheinz, J.P. Laneury, P. Duchene, S. Shedlofsky, R.A. Blouin, Stability of cephalosporin prodrug esters in human intestinal juice: implications for oral bioavailability, Antimicrob. Agents Chemother. 42 (1998) 2602-2606.
6. EMA (CHMP), Assessment Report for Zytiga (Abiraterone), 2011. .
7. FDA (CDER), Clinical Pharmacology and Biopharmaceutics Review(s) - Abiraterone Acetate, 2010. (accessed 15.09.14).
8. M. Acharya, M. Gonzalez, G. Mannens, R. De Vries, C. Lopez, T. Griffin, et al., A phase I, open-label, single-dose, mass balance study of 14C-labeled abiraterone acetate in healthy male subjects, Xenobiotica 43 (2013) 379-389, http://dx.doi.org/10.3109/00498254.2012.721022.
9. J. Bevernage, T. Forier, J. Brouwers, J. Tack, P. Annaert, P. Augustijns, Excipient-mediated supersaturation stabilization in human intestinal fluids, Mol. Pharm. 8 (2011) 564-570, http://dx.doi.org/10.1021/mp100377m.
10. D. Hörter, J.B. Dressman, Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract, Adv. Drug Deliv. Rev. 46 (2001) 75-87.
11. K. Beaumont, R. Webster, I. Gardner, K. Dack, Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: challenges to the discovery scientist, Curr. Drug Metab. 4 (2003) 461-485.
12. J. Bevernage, J. Brouwers, P. Annaert, P. Augustijns, Drug precipitation-permeation interplay: supersaturation in an absorptive environment, Eur. J. Pharm. Biopharm. 82 (2012) 424-428, http://dx.doi.org/10.1016/j.ejpb.2012.07.009.